logo

For the Inventor, By the Inventor

Tokyo, Japan

Shuichi Sakamoto

This inventor holds 24 USPTO granted patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Yamanouchi Pharmaceutical Company Ltd., Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Jeol Ltd.. Active years: 1984-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shuichi Sakamoto. Retrieved from https://idiyas.com/inventor/shuichi-sakamoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24

% Patents Active = 95.8

 

Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 183(Granted Patents)


Location History:

  • Kodaira, JP (1984)
  • Ushiku, JP (1994)
  • Ibaraki, JP (1997 - 2003)
  • Tokyo, JP (1984 - 2018)

Company Filing History:

goldMedal17 out of 329 
 
Yamanouchi Pharmaceutical Company Ltd.
 patents
silverMedal2 out of 212 
 
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
 patents
bronzeMedal1 out of 831 
 
Jeol Ltd.
 patents
4. 1 out of 43 
 
Medical Biological Laboratories Co., Ltd.
 patents
5. 1 out of 44 
 
Microbial Chemistry Research Foundation
 patents
6. 1 out of 70 
 
The Nisshin Oil Mills, Ltd.
 patents
7. 1 out of 1 
 
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (Microbial Chemistry Research
 patent
8. 1 out of 1 
 
Zaidan Hojin Biselbutsu Kagaku Kenkyu Kai (Microbial Chemistry Research
 patent
where one patent can have more than one assignee

Years Active: 1984-2018

Loading Chart...
Loading Chart...
Areas of Expertise:
Mycaminosyl Tylonolide Derivatives
Quinoxalinedione Derivatives
Thiazolobenzoimidazole Derivatives
Kainic Acid Neurotoxicity Inhibitor
Cycloalkylamino Derivatives
Bisphosphonic Acid Derivatives
Tricyclic Pyrrole Derivatives
Fused Pyrazine Derivatives
Pharmaceutical Compositions
Serine Derivative
3,5-Di-tert-butyl-4-hydroxyphenyl Compounds
N-(3-Pyrrolidinyl) Benzamide Derivative
24 patents (USPTO):Explore Patents
1. 9874532 - Scatter diagram display device and surface analyzer (2018-01-23),
2. 9416189 - Anti-CXADR antibody (2016-08-16),
3. 6642264 - Thiazolobenzoimidazole derivatives (2003-11-04),
4. 6245796 - Tricyclic pyrrole or pyrazole derivative (2001-06-12),
5. 6133258 - Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative (2000-10-17),
6. 6121264 - Imidazole-substituted quinoxalinedione derivatives (2000-09-19),
7. 6096743 - 1,2,3,4-tetrahydroquinoxalinedione derivative (2000-08-01),
8. 5834460 - Serine derivative (1998-11-10),
9. 5686482 - N-(3-pyrrolidinyl) benzamide derivative (1997-11-11),
10. 5283244 - Fused pyrazine derivatives (1994-02-01),
11. 5101022 - Mycaminosyl tylonolide derivatives (1992-03-31),
12. 5096888 - 3-deoxy mycaminosyl tylonolide derivatives (1992-03-17),
13. 5041428 - (Cycloalkylamino)methylenebis(phosphonic acid) and medicines contaiing (1991-08-20),
14. 4973576 - Bisphophonic acid derivatives and pharmaceutical compositions containing (1990-11-27),
15. 4970335 - (Cycloalkylamino)methylenebis(phosphonic acid) (1990-11-13),

Title: Shuichi Sakamoto: Innovator in Biotechnology and Analytical Devices

Introduction

Shuichi Sakamoto, based in Tokyo, Japan, is a prolific inventor with a remarkable portfolio of 24 patents. His inventions primarily focus on advancements in biotechnology and analytical devices, combining innovative scientific research with practical applications to enhance healthcare and data analysis.

Latest Patents

Among his most recent inventions, Sakamoto has developed a scatter diagram display device that employs principal component analysis for visualizing intensity or concentration map data of various elements. This device introduces a priority level setting section, organizing scatter diagrams derived from combination data, thereby improving data interpretation.

Additionally, Sakamoto has made strides in the field of cancer treatment with his anti-CXADR antibody patent. This innovation aims to identify a target molecule effective against cancer, particularly focusing on prostate, pancreatic, and colorectal cancer cells. The monoclonal antibody exhibited significant anti-cancer activity and could serve as an essential component for future anticancer therapies.

Career Highlights

Sakamoto has collaborated with some notable organizations, including Yamanouchi Pharmaceutical Company Ltd., where he contributed his expertise to pharmaceutical advancements. Additionally, his work with Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai demonstrates his commitment to ongoing research and innovation in life sciences.

Collaborations

Throughout his career, Sakamoto has worked alongside esteemed colleagues such as Sumio Umezawa and Tsutomu Tsuchiya. These collaborations have fostered a conducive environment for sharing knowledge and expertise, ultimately leading to pioneering developments in their respective fields.

Conclusion

Shuichi Sakamoto continues to be a significant figure in the realms of biotechnology and analytical device innovations. His impressive portfolio of patents not only showcases his inventive prowess but also highlights his dedication to addressing critical health issues through technology. His work promises to pave the way for future advancements that could greatly impact both the scientific community and society at large.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…